ClinicalTrials.gg

Program

Dacarbazine

Also written as “dacarbazine”, “Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)” and “dacarbazine plus Genasense”.

Its studies are mostly in Melanoma · Hodgkin Disease · Sarcoma, Alveolar Soft Part, led by Bayer.

Furthest: phase 2, since Jun 26, 20071 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer10 open or runningphase 2since Jun 26, 2007Jun 26, 2007none ahead

Also a collaborator on its studies: medarex and kudos-pharmaceuticals-limited.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 26, 2007First study: phase 2 study in MelanomaFirst studyNCT00492297 · 83 enrolled · France, United Kingdom

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00492297Melanoma · France, United Kingdom2CompletedJun 200883

How it is read

Names in the registry

  • “Dacarbazine”, 8 entries
  • “dacarbazine”, 3 entries
  • “Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)”, 1 entry
  • “dacarbazine plus Genasense”, 1 entry
  • “Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.